Series - BIO Benefits

As monoclonal antibody (mAb) programs approach IND, delays often stem from fragmented development, tech transfer complexity, and limited process efficiency.

In this webinar, Thermo Fisher Scientific presents a reengineered Path to IND for biologics platform that combines advanced platform science with integrated U.S.-based manufacturing to accelerate timelines and reduce risk.

Join our Head of Technical and Scientific Affairs to explore:

• Expanded mAb manufacturing capacity: Future drug substance and product capacity in Plainville, MA to ease constraints and increase availability at sites like Groningen (NL) and Lengnau (CH).
• Advanced CHO-K1 platform with AI/ML: High-performing CHO-K1 cell line and process intensification achieving up to 11 g/L,* and enhanced by AI/ML-driven vector design and clone optimization to boost expression, stability, and speed.
• Accelerated path to IND: End-to-end biologics platform delivering IND-ready material in as little as 8 months with titer levels of up to 8 g/L.*
• Integrated process characterization and validation: Risk-based approach to PC, PV, and tech transfer to strengthen process robustness and help to accelerate PPQ readiness.
• Risk-mitigated development approach: Combines QbD, stage-gate governance, and qualified scale-down models to help to reduce variability and enable more predictable scale-up.
• Flexible scale model: Single-use bioreactor strategy (500–5,000 L) across a global network to streamline tech transfer from development through commercial manufacturing.

Discover how integrating advanced cell line engineering, high-efficiency processes, and a unified U.S. manufacturing strategy can help bring your mAb therapy to IND faster—with greater control and confidence.

The Advanced Research Projects Agency for Health (ARPA-H) advances bold, innovative research to solve the most challenging health problems. Their programs span from fundamental science to translational medicine, driving breakthrough discoveries that transform patient care and public health outcomes. ARPA-H makes pivotal investments in breakthrough technologies and broadly applicable platforms, capabilities, resources, and solutions with the potential to transform important areas of medicine and health that cannot readily be accomplished through traditional research or commercial activity. ARPA-H solutions aim to benefit everyone. 

Join us to learn more about the ARPA-H Small Business Program, its research and funding programs, and opportunities for engagement during our upcoming webinar featuring ARPA-H’s Lead Program Specialist, Sam Gussman-Toh. 

This webinar is appropriate for companies at all stages of development who are interested in partnering with ARPA-H to bring their ideas to life. Topics to be covered include: 

• Funding opportunities, including those for small businesses 
• ARPA-H’s Small Business Innovation Research (SBIR) awards and Small Business Technology Transfer (STTR) solicitation 
• Engagement opportunities for industry, academia, government, and early adopters

Elevate your research with Google Cloud AI solutions for Healthcare and Life Sciences, designed to help your organization supercharge scientific breakthroughs. Join our upcoming webinar to discover how AI is helping to transform the laboratory landscape by automating the most time-consuming parts of the research cycle. 

From rapid hypothesis generation and intelligent experimental design to complex multi-modal data analysis, Google Cloud solutions like Co-Scientist, Alpha Genome, and Alpha Evolve can act as a force multiplier for your team. Learn how to: 

• Accelerate Discovery: Shorten the path from inquiry to impact with automated literature synthesis and real-time reasoning. 
• Optimize Workflows: Streamline lab operations and simulate experimental outcomes before picking up a pipette. 
• Unlock Innovation: Uncover hidden patterns in your data that traditional methods often miss. 

Whether you’re in drug discovery, materials science, or academic research, this webinar will show you how to merge human expertise with AI precision to stay at the forefront of innovation. Don’t miss the chance to see the future of science in action.

Is this the first time you’re attending BIO International Convention? This webinar is for you! You’ll get insider tips from the BIO team on how to maximize your time at BIO 2026 and learn what’s new this year at the largest event for biotechnology in the world. 

If you haven't already registered for BIO 2026, you can find more information on the BIO International Convention website.

Description
Global Out‑Licensing in a Dynamic Environment: Key Considerations for Biopharmaceutical Companies

The biopharmaceutical ecosystem is facing heightened uncertainty, driven by funding constraints, regulatory shifts, and policy reforms—including pricing pressures and the potential expansion of international reference pricing. These dynamics are reshaping dealmaking and raising critical questions for companies pursuing global out‑licensing strategies.

Join experts from Covington for a timely discussion on how these trends are influencing licensing decisions, with insights on:

• Structuring Out‑Licensing Agreements and Territory Splits – strategic and practical considerations
• Policy Impacts on Licensing – Key developments in the U.S. and EU
• Executing Near‑Term Deals – practical guidance in an evolving market

At the 2026 BIO International Convention, we come together Driven by Purpose to forge meaningful connections and advance innovations that improve lives. Successful partnering starts with a clear strategy, especially for biotech companies actively seeking licensing deals with pharmaceutical partners.

Join this focused panel discussion featuring pharmaceutical business development executives and biotech leaders pursuing pharma licensing partnerships at BIO 2026. Panelists will share practical, real-world guidance on how both sides approach partnering meetings, assess opportunities and build relationships that lead to successful deals.

In this session, you will hear insights on:

• How to prepare effectively for BIO
• What pharma teams look for in licensing partners and assets
• How biotechs can position their science and data for licensing discussions
• Using the BIO Partnering™ system strategically
• Turning meetings into next steps and deals

Learn directly from industry leaders who know what it takes to partner with purpose and to turn BIO partnering meetings into meaningful licensing outcomes.

Please join the BIO Exhibits and Partnering teams for an informative webinar designed specifically for exhibitors looking to maximize their booth partnering success. 

During this session, we will share practical tips, proven strategies, and best practices to help you optimize your presence, increase visibility, and drive meaningful connections on the exhibit floor.

We look forward to helping you make the most of your partnering opportunities.

​BIO would like to walk through three new offerings to BIO members:

1. BRIDGE – Given the rapidly evolving scientific and regulatory ecosystem, it is critical to have a real-time understanding of any shifts in regulatory predictability, efficiency, or regulator expectations. To address this gap, BIO is introducing BRIDGE (BIO Regulatory Issue Data Gathering & Engagement) to move from anecdotal feedback to a more structured data-collection framework that captures member-reported data on regulatory issues impacting the timely review and approval of an innovative drug or biologic regulated by the FDA. Through BRIDGE, BIO will systematically aggregate member data, identify trend-level regulatory challenges, and engage FDA as needed to improve visibility into areas of recurring friction.
2. Investor Connect Plus – An exclusive investor access program in partnership with LaunchBio for BIO members. This program facilitates targeted one-to-one meetings with institutional and strategic investors actively deploying capital. These monthly efforts will connect Launch Bio’s national network of curated investors with member companies and create meaningful pitch opportunities.
3. Tracxn – Another new partnership, Tracxn offers complimentary access to a database of 250K+ active global investors. A valuable tool to help you identify, screen, and connect with the right partners for your fundraising goals.

The 2026 BIO International Convention is Driven by Purpose—united by our shared mission to push boundaries, solve the impossible and achieve better outcomes for patients, public health, and the world. In that same spirit, BIO Partnering™ is designed to help you turn that purpose into action by connecting with the right partners, collaborators and investors who can help bring your innovations to life.

Join Mackensie Vernetti, BIO’s Vice President of Partnering, for a practical, purpose-driven walkthrough of how to use the BIO Partnering system effectively. This webinar will show you how to:

• Make use of the system’s newest features
• Create a compelling partnering profile that highlights your mission and capabilities
• Identify and evaluate potential partners who align with your goals
• Send targeted, effective meeting requests that lead to meaningful connections
• Manage your schedule and maximize your time at BIO 2026

BIO 2026 is where we return to our essential “why.” This session will help ensure you arrive ready to partner with purpose—and make every meeting count.